Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Actelion    ATLN   CH0010532478

ACTELION (ATLN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CHF)
Sales 2017 2 462 M
EBIT 2017 978 M
Net income 2017 -
Finance 2017 92,0 M
Yield 2017 -
Sales 2018 2 722 M
EBIT 2018 1 133 M
Net income 2018 -
Finance 2018 363 M
Yield 2018 -
P/E ratio 2017 32,59
P/E ratio 2018 28,08
EV / Sales2017 12,2x
EV / Sales2018 10,9x
Capitalization 30 079 M
More Financials
Company
Actelion Ltd. operates as a holding company with interests in developing, producing and marketing pharmaceutical drugs.It is a biopharmaceutical company, which focuses on the drug discovery, development, registration, production and commercialization of innovative drugs for diseases with... 
More about the company
Surperformance© ratings of Actelion
Trading Rating : - Investor Rating :
More Ratings
Latest news on ACTELION
2017 ACTELION : Pharmaceuticals Ltd - Cancellation of publicly held Actelion shares a..
2017 ACTELION : Cancellation of publicly held Actelion shares and delisting from SIX ..
2017 JOHNSON & JOHNSON : and Reports 2017 Third Quarter Results
2017 JOHNSON & JOHNSON : Fades With Profit, Forecast
2017 ACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
2017 JOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
2017 JOHNSON & JOHNSON : tops Street 3Q forecasts, hikes forecast
2017 JOHNSON & JOHNSON : Raises Guidance on Earnings Beat
2017 ACTELION : Receives FDA Approval Of TRACLEER® bosentan For Use In Pediatric Pati..
2017 ACTELION : receives FDA approval for 32mg Tracleer to treat paediatric PAH patie..
More news
Sector news : Bio Therapeutic Drugs
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
01/08 $11 billion biotech binge fuels forecasts of 2018 M&A surge
01/08 SANOFI : and Regeneron boost investment in cancer drug cemiplimab
01/07 ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance -- Updat..
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on ACTELION 
ACTELION LTD - 2016
A good timing to anticipate a change in the trend
BUY
ACTELION LTD - 2016
The calm spell can be taken advantage of to put on new positions
BUY
More Strategies
News from SeekingAlpha
2017 Cross-Border M&A Between U.S. And European Firms At 10-Year High
2017 Actelion (ALIOF) Investor Presentation - Slideshow
2017 Johnson & Johnson Lays Out Its Battle Plan
2017 SNIPPET ROUNDUP : Tesaro's Parp Pricing Stumble And Asco Sneak Peek
2017 JOHNSON & JOHNSON : No Surprises Here
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 262  CHF
Spread / Average Target -6,4%
EPS Revisions
Managers
NameTitle
Ludo Ooms Chairman
Julian Bertschinger Director
Claudio Cescato Director
Pascal Hoorn Director
Andrea Ostinelli Director
Sector and Competitors
1st jan.Capitalization (M$)
ACTELION27.10%0
GILEAD SCIENCES10.30%103 247
VERTEX PHARMACEUTICALS5.39%40 060
REGENERON PHARMACEUTICALS-2.39%39 566
GENMAB11.27%11 475
EXELIXIS, INC.-0.07%8 899